脂質異常症の世界市場レポート 2025年

脂質異常症の市場規模は、今後数年で急成長が見込まれます。2029年にはCAGR10.6％で270億4,000万米ドルに成長すると予想されます。予測期間中に予想される成長は、脂質低下療法の進歩、認知度の向上とスクリーニングプログラム、代謝異常の有病率の上昇、医療費の増加、脂質異常症の有病率の増加などの要因に起因しています。この期間の主な動向には、遺伝子治療の進展、RNAベースの治療の革新、AI主導の創薬の進展、個別化医療の発展、デジタルヘルスモニタリングの進展などがあります。

肥満人口の増加が脂質異常症市場の拡大を牽引すると予想されます。健康に悪影響を及ぼす過剰な体脂肪を特徴とする肥満は、長引くエネルギー不均衡を引き起こすライフスタイルの変化により蔓延しつつあり、緩やかな体重増加と関連する健康問題につながっています。肥満は脂質代謝を乱し、コレステロールやトリグリセリドの異常値をもたらし、心血管疾患のリスクを高めることによって脂質異常症の原因となります。例えば、スイスに本部を置く政府間機関である世界保健機関（WHO）は2024年3月、18歳以上の成人25億人を含む、世界の約8人に1人が肥満の影響を受けていると報告しました。さらに、5歳未満の子どものうち3,700万人が肥満と分類されました。この肥満率の上昇は、脂質異常症市場の重要な促進要因です。

脂質異常症市場の主要企業は、治療成績を改善し、患者のアドヒアランスを高め、複数の脂質不均衡に同時に対処するための新興国併用療法の開発に注力しています。先進的併用療法では、2種類以上の治療薬を単一のレジメンで使用することで、有効性を高め、副作用を最小限に抑え、疾患のさまざまなメカニズムを標的とします。例えば、2024年3月、米国の製薬会社Esperion Therapeutics Inc.は、同社の医薬品であるNEXLETOL（ベンペド酸）とNEXLIZET（ベンペド酸とエゼチミブの配合剤）が米国政府機関である食品医薬品局（FDA）から承認されたと発表しました。これらの先進的な非スタチン系経口治療薬は、低比重リポ蛋白コレステロール（LDL-C）を低下させ、心血管イベントのリスクを低減するよう設計されています。これらの薬剤のラベルが更新されたことにより、コレステロールを低下させるために一般的に処方されるスタチン系薬剤と単独または併用で使用できるようになりました。この柔軟性は、スタチン非耐性患者やスタチン以外の治療法を好む患者にとって特に有益です。

目次

第1章 エグゼクティブサマリー

第2章 市場の特徴

第3章 市場動向と戦略

第4章 市場- マクロ経済シナリオ金利、インフレ、地政学、新型コロナウイルス感染症の影響と回復が市場に与える影響を含むマクロ経済シナリオ

第5章 世界の成長分析と戦略分析フレームワーク

• 世界の脂質異常症市場のPESTEL分析（政治、社会、技術、環境、法的要因、促進要因、抑制要因）
• 最終用途産業の分析
• 世界の脂質異常症市場：成長率分析
• 世界の脂質異常症市場の実績：規模と成長、2019～2024年
• 世界の脂質異常症市場の予測：規模と成長、2024～2029年、2034年
• 世界の脂質異常症総アドレス可能市場（TAM）

第6章 市場セグメンテーション

• 世界の脂質異常症市場：治療別、実績と予測、2019～2024年、2024～2029年、2034年
• スタチン
• 胆汁酸吸着剤
• PCSK9阻害剤
• 低分子干渉RNA（siRNA）
• コレステロール吸収阻害剤
• フィブラート
• ナイアシン
• オメガ3脂肪酸誘導体
• その他
• 世界の脂質異常症市場：投与経路別、実績と予測、2019～2024年、2024～2029年、2034年
• 経口
• 非経口
• 世界の脂質異常症市場：流通チャネル別、実績と予測、2019～2024年、2024～2029年、2034年
• 病院薬局
• 小売薬局
• ドラッグストア
• オンライン薬局
• 世界の脂質異常症市場：スタチンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• アトルバスタチン
• シンバスタチン
• ロスバスタチン
• プラバスタチン
• 世界の脂質異常症市場：胆汁酸吸着剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• コレスチラミン
• コレセベラム
• 世界の脂質異常症市場：PCSK9阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エボロクマブ
• アリロクマブ
• 世界の脂質異常症市場：低分子干渉RNA（siRNA）のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• インクリシラン
• 世界の脂質異常症市場：コレステロール吸収阻害剤のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エゼチミブ
• 世界の脂質異常症市場：フィブラートのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• フェノフィブラート
• ゲムフィブロジル
• 世界の脂質異常症市場：ナイアシンのサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ニコチン酸
• 世界の脂質異常症市場：オメガ3脂肪酸誘導体のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• エイコサペンタエン酸（EPA）
• ドコサヘキサエン酸（DHA）
• 世界の脂質異常症市場：その他のサブセグメンテーション：タイプ別、実績と予測、2019～2024年、2024～2029年、2034年
• ハーブサプリメント
• 併用療法

第7章 地域別・国別分析

• 世界の脂質異常症市場：地域別、実績と予測、2019～2024年、2024～2029年、2034年
• 世界の脂質異常症市場：国別、実績と予測、2019～2024年、2024～2029年、2034年

第8章 アジア太平洋市場

第9章 中国市場

第10章 インド市場

第11章 日本市場

第12章 オーストラリア市場

第13章 インドネシア市場

第14章 韓国市場

第15章 西欧市場

第16章 英国市場

第17章 ドイツ市場

第18章 フランス市場

第19章 イタリア市場

第20章 スペイン市場

第21章 東欧市場

第22章 ロシア市場

第23章 北米市場

第24章 米国市場

第25章 カナダ市場

第26章 南米市場

第27章 ブラジル市場

第28章 中東市場

第29章 アフリカ市場

第30章 競合情勢と企業プロファイル

• 脂質異常症市場：競合情勢
• 脂質異常症市場：企業プロファイル
  • Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • Novartis AG Overview, Products and Services, Strategy and Financial Analysis

第31章 その他の大手企業と革新的企業

• Eli Lilly and Company
• Amgen Inc.
• Viatris Inc.
• Teva Pharmaceutical Industries Ltd.
• Daiichi Sankyo Company Limited
• Zydus Lifesciences Ltd.
• Lupin Pharmaceuticals Inc.
• Alnylam Pharmaceuticals Inc.
• Amarin Corporation
• Esperion Therapeutics Inc.
• Arrowhead Pharmaceuticals Inc.
• Outsource Strategies International
• Catabasis Pharmaceuticals
• NewAmsterdam Pharma Holding BV
• JW Pharmaceutical

第32章 世界の市場競合ベンチマーキングとダッシュボード

第33章 主要な合併と買収

第34章 最近の市場動向

第35章 市場の潜在力が高い国、セグメント、戦略

• 脂質異常症市場2029：新たな機会を提供する国
• 脂質異常症市場2029：新たな機会を提供するセグメント
• 脂質異常症市場2029：成長戦略
  • 市場動向に基づく戦略
  • 競合の戦略

第36章 付録

Dyslipidemia is a condition in which the levels of lipids (fats) in the blood become abnormal. The goal of managing dyslipidemia is to regulate lipid levels, reduce the risk of cardiovascular diseases, and enhance heart health through a combination of lifestyle changes, medication, and regular monitoring.

The primary treatment options for dyslipidemia include statins, bile acid sequestrants, PCSK9 inhibitors, small interfering RNA (siRNA), cholesterol absorption inhibitors, fibrates, niacins, omega-3 fatty acid derivatives, and others. Statins are medications that lower cholesterol by inhibiting the enzyme HMG-CoA reductase, which is crucial for cholesterol production in the liver. These treatments are administered through various routes, such as oral and parenteral, and are distributed through various channels, including hospital pharmacies, retail pharmacies, drug stores, and online pharmacies.

The dyslipidemia market research report is one of a series of new reports from The Business Research Company that provides dyslipidemia market statistics, including the dyslipidemia industry global market size, regional shares, competitors with the dyslipidemia market share, detailed dyslipidemia market segments, market trends, and opportunities, and any further data you may need to thrive in the dyslipidemia industry. This dyslipidemia market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenarios of the industry.

The dyslipidemia market size has grown rapidly in recent years. It will grow from $16.31 billion in 2024 to $18.08 billion in 2025 at a compound annual growth rate (CAGR) of 10.8%. The growth observed in the historical period can be attributed to factors such as a rising genetic predisposition, an increasingly sedentary lifestyle, the growing consumption of unhealthy diets, an aging population, and escalating obesity rates.

The dyslipidemia market size is expected to see rapid growth in the next few years. It will grow to $27.04 billion in 2029 at a compound annual growth rate (CAGR) of 10.6%. The growth anticipated during the forecast period can be attributed to factors such as advancements in lipid-lowering therapies, increased awareness and screening programs, the rising prevalence of metabolic disorders, higher healthcare expenditure, and the growing prevalence of dyslipidemia. Key trends during this period include advancements in gene therapies, innovations in RNA-based treatments, progress in AI-driven drug discovery, developments in personalized medicine, and advancements in digital health monitoring.

The growing obese population is expected to drive the expansion of the dyslipidemia market. Obesity, characterized by excess body fat that negatively impacts health, is becoming more prevalent due to lifestyle changes that cause prolonged energy imbalances, leading to gradual weight gain and associated health problems. Obesity contributes to dyslipidemia by disrupting lipid metabolism, resulting in abnormal cholesterol and triglyceride levels, which increase the risk of cardiovascular diseases. For example, in March 2024, the World Health Organization (WHO), a Switzerland-based intergovernmental organization, reported that approximately one in eight people worldwide are affected by obesity, including 2.5 billion adults aged 18 and older. Additionally, 37 million children under five years old were classified as overweight. This rising rate of obesity is a significant driver of the dyslipidemia market.

Leading companies in the dyslipidemia market are focusing on developing advanced combination therapies to improve treatment outcomes, enhance patient adherence, and address multiple lipid imbalances simultaneously. Advanced combination therapies involve using two or more therapeutic agents in a single regimen to improve efficacy, minimize side effects, and target various mechanisms of the disease. For instance, in March 2024, Esperion Therapeutics Inc., a US-based pharmaceutical company, announced that its medications NEXLETOL (bempedoic acid) and NEXLIZET (a combination of bempedoic acid and ezetimibe) were approved by the Food and Drug Administration (FDA), a US government agency. These advanced, non-statin oral treatments are designed to lower low-density lipoprotein cholesterol (LDL-C) and reduce the risk of cardiovascular events. The updated labels for these drugs allow them to be used alone or in combination with statins, which are commonly prescribed to lower cholesterol. This flexibility is especially beneficial for patients who cannot tolerate statins or prefer non-statin treatment options.

In July 2022, NewAmsterdam Pharma Holding BV, a Netherlands-based biopharmaceutical company focused on treating dyslipidemia, entered into a merger agreement with Frazier Lifesciences Acquisition Corporation. Through this merger, NewAmsterdam aims to develop obicetrapib, a next-generation, low-dose, once-daily CETP inhibitor designed for patients with dyslipidemia who are at high risk for cardiovascular disease. Frazier Lifesciences Acquisition Corporation, a US-based healthcare company, specializes in novel therapeutics.

Major players in the dyslipidemia market are Pfizer Inc., Merck & Co. Inc., Sanofi SA, AstraZeneca plc, Novartis AG, Eli Lilly and Company, Amgen Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Daiichi Sankyo Company Limited, Zydus Lifesciences Ltd., Lupin Pharmaceuticals Inc., Alnylam Pharmaceuticals Inc., Amarin Corporation, Esperion Therapeutics Inc., Arrowhead Pharmaceuticals Inc., Outsource Strategies International, Catabasis Pharmaceuticals, NewAmsterdam Pharma Holding BV, JW Pharmaceutical.

North America was the largest region in the dyslipidemia market in 2024. Asia-pacific is expected to be the fastest-growing region in the forecast period. The regions covered in dyslipidemia report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the dyslipidemia market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The dyslipidemia market consists of revenues earned by entities by providing services such as diagnosis, lipid profile testing, medical consultations, lifestyle counseling, prescription, and advanced therapeutic interventions for managing abnormal lipid levels. The market value includes the value of related goods sold by the service provider or included within the service offering. The dyslipidemia market also includes sales of products such as ezetimibe combination drugs, adenosine triphosphate-citrate lyase (ACL) inhibitors, and bempedoic acid combination drugs. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors, and retailers) or directly to end customers. The value of goods in this market includes related services sold by the creators of the goods.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD unless otherwise specified).

The revenues for a specified geography are consumption values and are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Dyslipidemia Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on dyslipidemia market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

• Gain a truly global perspective with the most comprehensive report available on this market covering 15 geographies.
• Assess the impact of key macro factors such as conflict, pandemic and recovery, inflation and interest rate environment and the 2nd Trump presidency.
• Create regional and country strategies on the basis of local data and analysis.
• Identify growth segments for investment.
• Outperform competitors using forecast data and the drivers and trends shaping the market.
• Understand customers based on the latest market shares.
• Benchmark performance against key competitors.
• Suitable for supporting your internal and external presentations with reliable high quality data and analysis
• Report will be updated with the latest data and delivered to you within 2-3 working days of order along with an Excel data sheet for easy data extraction and analysis.
• All data from the report will also be delivered in an excel dashboard format.

Where is the largest and fastest growing market for dyslipidemia ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The dyslipidemia market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

• The market characteristics section of the report defines and explains the market.
• The market size section gives the market size ($b) covering both the historic growth of the market, and forecasting its development.
• The forecasts are made after considering the major factors currently impacting the market. These include:

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

• Market segmentations break down the market into sub markets.
• The regional and country breakdowns section gives an analysis of the market in each geography and the size of the market by geography and compares their historic and forecast growth. It covers the growth trajectory of COVID-19 for all regions, key developed countries and major emerging markets.
• The competitive landscape chapter gives a description of the competitive nature of the market, market shares, and a description of the leading companies. Key financial deals which have shaped the market in recent years are identified.
• The trends and strategies section analyses the shape of the market as it emerges from the crisis and suggests how companies can grow as the market recovers.

Scope

• Markets Covered:1) By Treatment: Statins; Bile Acid Sequestrants; PCSK9 Inhibitors; Small Interfering RNA (siRNA); Cholesterol Absorption Inhibitors; Fibrates; Niacins; Omega-3 Fatty Acid Derivatives; Other Treatments
• 2) By Route Of Administration: Oral; Parental
• 3) By Distribution Channel: Hospital Pharmacies; Retail Pharmacies; Drug Store; Online Pharmacies
• Sub Segments:
• 1) By Statins: Atorvastatin; Simvastatin; Rosuvastatin; Pravastatin
• 2) By Bile Acid Sequestrants: Cholestyramine; Colesevelam
• 3) By PCSK9 Inhibitors: Evolocumab; Alirocumab
• 4) By Small Interfering RNA (siRNA): Inclisiran
• 5) By Cholesterol Absorption Inhibitors: Ezetimibe
• 6) By Fibrates: Fenofibrate; Gemfibrozil
• 7) By Niacins: Nicotinic Acid
• 8) By Omega-3 Fatty Acid Derivatives: Eicosapentaenoic Acid (EPA); Docosahexaenoic Acid (DHA)
• 9) By Other Treatments: Herbal Supplements; Combination Therapies
• Companies Mentioned: Pfizer Inc.; Merck & Co. Inc.; Sanofi SA; AstraZeneca plc; Novartis AG
• Countries: Australia; Brazil; China; France; Germany; India; Indonesia; Japan; Russia; South Korea; UK; USA; Canada; Italy; Spain
• Regions: Asia-Pacific; Western Europe; Eastern Europe; North America; South America; Middle East; Africa
• Time series: Five years historic and ten years forecast.
• Data: Ratios of market size and growth to related markets, GDP proportions, expenditure per capita,
• Data segmentations: country and regional historic and forecast data, market share of competitors, market segments.
• Sourcing and Referencing: Data and analysis throughout the report is sourced using end notes.
• Delivery format: PDF, Word and Excel Data Dashboard.

Table of Contents

1. Executive Summary

2. Dyslipidemia Market Characteristics

3. Dyslipidemia Market Trends And Strategies

4. Dyslipidemia Market - Macro Economic Scenario Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics And Covid And Recovery On The Market

5. Global Dyslipidemia Growth Analysis And Strategic Analysis Framework

• 5.1. Global Dyslipidemia PESTEL Analysis (Political, Social, Technological, Environmental and Legal Factors, Drivers and Restraints)
• 5.2. Analysis Of End Use Industries
• 5.3. Global Dyslipidemia Market Growth Rate Analysis
• 5.4. Global Dyslipidemia Historic Market Size and Growth, 2019 - 2024, Value ($ Billion)
• 5.5. Global Dyslipidemia Forecast Market Size and Growth, 2024 - 2029, 2034F, Value ($ Billion)
• 5.6. Global Dyslipidemia Total Addressable Market (TAM)

6. Dyslipidemia Market Segmentation

• 6.1. Global Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Statins
• Bile Acid Sequestrants
• PCSK9 Inhibitors
• Small Interfering RNA (siRNA)
• Cholesterol Absorption Inhibitors
• Fibrates
• Niacins
• Omega-3 Fatty Acid Derivatives
• Other Treatments
• 6.2. Global Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Oral
• Parental
• 6.3. Global Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Hospital Pharmacies
• Retail Pharmacies
• Drug Store
• Online Pharmacies
• 6.4. Global Dyslipidemia Market, Sub-Segmentation Of Statins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Atorvastatin
• Simvastatin
• Rosuvastatin
• Pravastatin
• 6.5. Global Dyslipidemia Market, Sub-Segmentation Of Bile Acid Sequestrants, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Cholestyramine
• Colesevelam
• 6.6. Global Dyslipidemia Market, Sub-Segmentation Of PCSK9 Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Evolocumab
• Alirocumab
• 6.7. Global Dyslipidemia Market, Sub-Segmentation Of Small Interfering RNA (siRNA), By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Inclisiran
• 6.8. Global Dyslipidemia Market, Sub-Segmentation Of Cholesterol Absorption Inhibitors, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Ezetimibe
• 6.9. Global Dyslipidemia Market, Sub-Segmentation Of Fibrates, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Fenofibrate
• Gemfibrozil
• 6.10. Global Dyslipidemia Market, Sub-Segmentation Of Niacins, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Nicotinic Acid
• 6.11. Global Dyslipidemia Market, Sub-Segmentation Of Omega-3 Fatty Acid Derivatives, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Eicosapentaenoic Acid (EPA)
• Docosahexaenoic Acid (DHA)
• 6.12. Global Dyslipidemia Market, Sub-Segmentation Of Other Treatments, By Type, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• Herbal Supplements
• Combination Therapies

7. Dyslipidemia Market Regional And Country Analysis

• 7.1. Global Dyslipidemia Market, Split By Region, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 7.2. Global Dyslipidemia Market, Split By Country, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

8. Asia-Pacific Dyslipidemia Market

• 8.1. Asia-Pacific Dyslipidemia Market Overview
• Region Information, Market Information, Background Information, Government Initiatives, Regulations, Regulatory Bodies, Major Associations, Taxes Levied, Corporate Tax Structure, Investments, Major Companies
• 8.2. Asia-Pacific Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.3. Asia-Pacific Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 8.4. Asia-Pacific Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

9. China Dyslipidemia Market

• 9.1. China Dyslipidemia Market Overview
• 9.2. China Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.3. China Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion
• 9.4. China Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F,$ Billion

10. India Dyslipidemia Market

• 10.1. India Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.2. India Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 10.3. India Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

11. Japan Dyslipidemia Market

• 11.1. Japan Dyslipidemia Market Overview
• 11.2. Japan Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.3. Japan Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 11.4. Japan Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

12. Australia Dyslipidemia Market

• 12.1. Australia Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.2. Australia Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 12.3. Australia Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

13. Indonesia Dyslipidemia Market

• 13.1. Indonesia Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.2. Indonesia Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 13.3. Indonesia Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

14. South Korea Dyslipidemia Market

• 14.1. South Korea Dyslipidemia Market Overview
• 14.2. South Korea Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.3. South Korea Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 14.4. South Korea Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

15. Western Europe Dyslipidemia Market

• 15.1. Western Europe Dyslipidemia Market Overview
• 15.2. Western Europe Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.3. Western Europe Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 15.4. Western Europe Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

16. UK Dyslipidemia Market

• 16.1. UK Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.2. UK Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 16.3. UK Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

17. Germany Dyslipidemia Market

• 17.1. Germany Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.2. Germany Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 17.3. Germany Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

18. France Dyslipidemia Market

• 18.1. France Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.2. France Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 18.3. France Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

19. Italy Dyslipidemia Market

• 19.1. Italy Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.2. Italy Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 19.3. Italy Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

20. Spain Dyslipidemia Market

• 20.1. Spain Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.2. Spain Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 20.3. Spain Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

21. Eastern Europe Dyslipidemia Market

• 21.1. Eastern Europe Dyslipidemia Market Overview
• 21.2. Eastern Europe Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.3. Eastern Europe Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 21.4. Eastern Europe Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

22. Russia Dyslipidemia Market

• 22.1. Russia Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.2. Russia Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 22.3. Russia Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

23. North America Dyslipidemia Market

• 23.1. North America Dyslipidemia Market Overview
• 23.2. North America Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.3. North America Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 23.4. North America Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

24. USA Dyslipidemia Market

• 24.1. USA Dyslipidemia Market Overview
• 24.2. USA Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.3. USA Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 24.4. USA Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

25. Canada Dyslipidemia Market

• 25.1. Canada Dyslipidemia Market Overview
• 25.2. Canada Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.3. Canada Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 25.4. Canada Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

26. South America Dyslipidemia Market

• 26.1. South America Dyslipidemia Market Overview
• 26.2. South America Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.3. South America Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 26.4. South America Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

27. Brazil Dyslipidemia Market

• 27.1. Brazil Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.2. Brazil Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 27.3. Brazil Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

28. Middle East Dyslipidemia Market

• 28.1. Middle East Dyslipidemia Market Overview
• 28.2. Middle East Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.3. Middle East Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 28.4. Middle East Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

29. Africa Dyslipidemia Market

• 29.1. Africa Dyslipidemia Market Overview
• 29.2. Africa Dyslipidemia Market, Segmentation By Treatment, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.3. Africa Dyslipidemia Market, Segmentation By Route Of Administration, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion
• 29.4. Africa Dyslipidemia Market, Segmentation By Distribution Channel, Historic and Forecast, 2019-2024, 2024-2029F, 2034F, $ Billion

30. Dyslipidemia Market Competitive Landscape And Company Profiles

• 30.1. Dyslipidemia Market Competitive Landscape
• 30.2. Dyslipidemia Market Company Profiles
  • 30.2.1. Pfizer Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.2. Merck & Co. Inc. Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.3. Sanofi SA Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.4. AstraZeneca plc Overview, Products and Services, Strategy and Financial Analysis
  • 30.2.5. Novartis AG Overview, Products and Services, Strategy and Financial Analysis

31. Dyslipidemia Market Other Major And Innovative Companies

• 31.1. Eli Lilly and Company
• 31.2. Amgen Inc.
• 31.3. Viatris Inc.
• 31.4. Teva Pharmaceutical Industries Ltd.
• 31.5. Daiichi Sankyo Company Limited
• 31.6. Zydus Lifesciences Ltd.
• 31.7. Lupin Pharmaceuticals Inc.
• 31.8. Alnylam Pharmaceuticals Inc.
• 31.9. Amarin Corporation
• 31.10. Esperion Therapeutics Inc.
• 31.11. Arrowhead Pharmaceuticals Inc.
• 31.12. Outsource Strategies International
• 31.13. Catabasis Pharmaceuticals
• 31.14. NewAmsterdam Pharma Holding BV
• 31.15. JW Pharmaceutical

32. Global Dyslipidemia Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Dyslipidemia Market

34. Recent Developments In The Dyslipidemia Market

35. Dyslipidemia Market High Potential Countries, Segments and Strategies

• 35.1 Dyslipidemia Market In 2029 - Countries Offering Most New Opportunities
• 35.2 Dyslipidemia Market In 2029 - Segments Offering Most New Opportunities
• 35.3 Dyslipidemia Market In 2029 - Growth Strategies
  • 35.3.1 Market Trend Based Strategies
  • 35.3.2 Competitor Strategies

36. Appendix

• 36.1. Abbreviations
• 36.2. Currencies
• 36.3. Historic And Forecast Inflation Rates
• 36.4. Research Inquiries
• 36.5. The Business Research Company
• 36.6. Copyright And Disclaimer